@article {Chaar5242作者={大卫Chaar和Mihir Kakara Shitiz Sriwastava和Sasan Moshirzadeh和卤代烷和罗伯特·米甲Lisak}, title = {Anti-MAG相关神经病变患者的特征响应利妥昔单抗(5242)},体积={94}={15}补充数量,elocation-id ={5242} ={2020},出版商= {Wolters Kluwer健康,公司代表美国神经病学学会},文摘={目的:评估患者的长期反应与利妥昔单抗和描述的特征与有利的结果。首页背景:Anti-myelin相关糖蛋白(MAG)神经病变是一种使人衰弱的paraproteinemic脱髓鞘病变。免疫疗法的效果一直不一致的多个研究;然而,利妥昔单抗{\ textemdash} b细胞消耗代理{\ textemdash}已被证明是有利于患者的一个子集。设计/方法:7 anti-MAG神经病变患者利妥昔单抗的病例分析。记录了人口、血清学和电诊法的特性。结果来评估疗效包括改良Rankin规模(夫人)和炎性病变病因和治疗(INCAT)规模。结果:86 \ %的患者是白人男性。在诊断上,平均年龄57岁,平均anti-MAG效价在急救员和1:513,600 1:40,000无(p = 0.04)。疾病治疗开始之前被4 {\ textpm} 3年反应者,相比11 {\ textpm} 7年无(p = 0.05)。滴度下降了7.5 {\ textpm} 4.7折后治疗。在12个月的治疗后,病人4/7报道症状改善感觉异常、异常性疼痛、震颤和步态。远端神经系统检查显示复苏强度、振动和本体感受解决伯格{\ textquoteright}年代标志,和下肢反射的复兴。 INCAT (mRS) score improved by 1.8{\textpm}1.0, (p=0.01) (1.3{\textpm}0.5, p=0.004) points from a baseline of 3.0{\textpm}1.6 (2.3{\textpm}0.5). Terminal latency index (TLI) of the median nerve was 0.30{\textpm}0.05. The remaining patients did not have further deterioration in their symptoms, exam or scores. One patient had lambda light-chains, unlike the others with kappa light-chains, and did not improve. Another elderly patient with TLI of 0.18 did not respond either despite a 9-fold reduction in anti-MAG titer.Conclusions: Features of rituximab responders include shorter disease-duration, lower anti-MAG titers and TLI\>0.25. Non-responders did not deteriorate further and remained stable. This retrospective case-series supports rituximab as a viable option in a subset of patients for management of anti-MAG neuropathy, with improvements in symptoms, neurological exam and functional neuropathy scales.Disclosure: Dr. Chaar has nothing to disclose. Dr. Kakara has nothing to disclose. Dr. Sriwastava has nothing to disclose. Dr. Moshirzadeh has nothing to disclose. Dr. Halon has nothing to disclose. Dr. Lisak has received personal compensation for consulting, serving on a scientific advisory board, speaking, or other activities with Alexion, Argenix, Novartis, Syntimmune, Teva Pharmaceuticals (non-branded talks), Alpha Sites, Clearview Consulting, Destum, GLG consulting, Haven Consulting, Informa Consulting, Insights Pharma Consulting, Slingshot Consulting. Dr. Lisak has received research support from Catalyst, Chungai, Genentec/Roche, Mallinckdrot, Medimmune, Novartis, Ra Pharmaceuticals, Teva Phamaceuticals.}, issn = {0028-3878}, URL = {//www.ez-admanager.com/content/94/15_Supplement/5242}, eprint = {//www.ez-admanager.com/content}, journal = {Neurology} }